Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 30, 2010Current Opinion in Lipidology

Interleukin-17: friend or foe in atherosclerosis?

View Full Paper
Ask AI
Bookmark
Share

Authors

STSoraya TalebGeneral / Preventive / LipidsAlain TedguiAlain TedguiVascular MedicineZMZiad MallatGeneral Cardiology

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Taleb et al. (2010) studied this question.

synapsesocial.com/papers/6a23135f03420c63e31ce9d3https://doi.org/10.1097/mol.0b013e32833dc7f9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation2003 · 1,669 citations
  2. 2Blockade of Interleukin-17A Results in Reduced Atherosclerosis in Apolipoprotein E–Deficient Mice2010 · 422 citations
  3. 3Interleukin-17 and Type 17 Helper T Cells2009 · 1,421 citations
  4. 4Interleukin-17 and Interferon-γ Are Produced Concomitantly by Human Coronary Artery–Infiltrating T Cells and Act Synergistically on Vascular Smooth Muscle Cells2009 · 412 citations
  5. 5Differential expression of interleukin‐17 family cytokines in intact and complicated human atherosclerotic plaques2009 · 183 citations